US2015157765A1PendingUtilityA1

Compositions for Regenerating Defective or Absent Myocardium

70
Assignee: CORMATRIX CARDIOVASCULAR INCPriority: Jul 15, 2005Filed: Feb 19, 2015Published: Jun 11, 2015
Est. expiryJul 15, 2025(expired)· nominal 20-yr term from priority
Inventors:Robert G. Matheny
A61K 31/726A61L 27/367A61K 38/1825A61K 35/37A61L 2430/30A61L 27/3683A61L 2430/20A61L 27/227A61K 9/0019A61K 38/1741A61K 35/34A61L 2400/06A61L 2300/64A61K 48/00A61L 2300/414A61L 27/3834A61L 2300/426A61L 27/3687A61L 27/3633A61L 27/3629A61K 38/39A61K 35/22A61L 2300/412A61K 35/545A61K 31/7088A61K 35/407A61L 27/3873A61L 2300/45A61K 38/1841A61K 35/50A61K 35/38A61L 27/58A61L 27/54A61L 27/40A61K 35/28A61K 31/711A61K 31/7105A61L 27/3804
70
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Injectable collagen based graft compositions and grafts formed from the compositions for tissue regeneration. The compositions and grafts further include a glycosaminoglycan (GAG) to control matrix formation and remodeling.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . An injectable graft composition for myocardial tissue regeneration, comprising extracellular matrix (ECM) from a mammalian tissue source comprising acellular small intestine submucosa, said ECM comprising endogenous glycosaminoglycans (GAGs), transforming growth factor beta (TGF-β) and fibroblast growth factor-2 (FGF-2), said ECM further comprising an exogenously added mesenchymal stem cell (MSC), wherein a MSC augmented ECM composition is formed,
 and wherein, when said MSC augmented ECM composition is administered to damaged myocardial tissue, said MSC augmented ECM composition induces remodeling of said damaged myocardial tissue and regeneration of new myocardial tissue. 
 
     
     
         2 . The composition of  claim 1 , wherein said composition further comprises an exogenously added cytokine. 
     
     
         3 . An injectable graft composition for myocardial tissue regeneration, comprising acellular heart extracellular matrix (ECM), said ECM comprising endogenous glycosaminoglycans (GAGs), transforming growth factor beta (TGF-β) and fibroblast growth factor-2 (FGF-2), said ECM further comprising an exogenously added mesenchymal stem cell (MSC), wherein a MSC augmented ECM composition is formed,
 and wherein, when said MSC augmented ECM composition is administered to damaged myocardial tissue, said MSC augmented ECM composition induces remodeling of said damaged myocardial tissue and regeneration of new myocardial tissue. 
 
     
     
         4 . The composition of  claim 3 , wherein said composition further comprises an exogenously added cytokine. 
     
     
         5 . An injectable graft composition for myocardial tissue regeneration, comprising extracellular matrix (ECM) from a mammalian tissue source comprising acellular urinary bladder submucosa, said ECM comprising endogenous glycosaminoglycans (GAGs), transforming growth factor beta (TGF-β) and fibroblast growth factor-2 (FGF-2), said ECM further comprising an exogenously added mesenchymal stem cell (MSC), wherein a MSC augmented ECM composition is formed,
 and wherein, when said MSC augmented ECM composition is administered to damaged myocardial tissue, said MSC augmented ECM composition induces remodeling of said damaged myocardial tissue and regeneration of new myocardial tissue. 
 
     
     
         6 . The composition of  claim 5 , wherein said composition further comprises an exogenously added cytokine. 
     
     
         7 . An injectable graft composition for myocardial tissue regeneration, comprising extracellular matrix (ECM) from a mammalian tissue source comprising acellular urinary bladder membrane, said ECM comprising endogenous glycosaminoglycans (GAGs), transforming growth factor beta (TGF-β) and fibroblast growth factor-2 (FGF-2), said ECM further comprising an exogenously added mesenchymal stem cell (MSC), wherein a MSC augmented ECM composition is formed,
 and wherein, when said MSC augmented ECM composition is administered to damaged myocardial tissue, said MSC augmented ECM composition induces remodeling of said damaged myocardial tissue and regeneration of new myocardial tissue. 
 
     
     
         8 . The composition of  claim 7 , wherein said composition further comprises an exogenously added cytokine. 
     
     
         9 . An injectable graft composition for myocardial tissue regeneration, comprising extracellular matrix (ECM) from a mammalian tissue source comprising acellular liver basement membrane, said ECM comprising endogenous glycosaminoglycans (GAGs), transforming growth factor beta (TGF-β) and fibroblast growth factor-2 (FGF-2), said ECM further comprising an exogenously added mesenchymal stem cell (MSC), wherein a MSC augmented ECM composition is formed,
 and wherein, when said MSC augmented ECM composition is administered to damaged myocardial tissue, said MSC augmented ECM composition induces remodeling of said damaged myocardial tissue and regeneration of new myocardial tissue. 
 
     
     
         10 . The composition of  claim 9 , wherein said composition further comprises an exogenously added cytokine. 
     
     
         11 . An injectable graft composition for myocardial tissue regeneration, comprising extracellular matrix (ECM) from a mammalian tissue source comprising acellular stomach submucosa, said ECM comprising endogenous glycosaminoglycans (GAGs), transforming growth factor beta (TGF-β) and fibroblast growth factor-2 (FGF-2), said ECM further comprising an exogenously added mesenchymal stem cell (MSC), wherein a MSC augmented ECM composition is formed,
 and wherein, when said MSC augmented ECM composition is administered to damaged myocardial tissue, said MSC augmented ECM composition induces remodeling of said damaged myocardial tissue and regeneration of new myocardial tissue. 
 
     
     
         12 . The composition of  claim 11 , wherein said composition further comprises an exogenously added cytokine. 
     
     
         13 . An injectable graft composition for myocardial tissue regeneration, comprising acellular placental extracellular matrix (ECM), said ECM comprising endogenous glycosaminoglycans (GAGS), transforming growth factor beta (TGF-β) and fibroblast growth factor-2 (FGF-2), said ECM further comprising an exogenously added mesenchymal stem cell (MSC), wherein a MSC augmented ECM composition is formed,
 and wherein, when said MSC augmented ECM composition is administered to damaged myocardial tissue, said MSC augmented ECM composition induces remodeling of said damaged myocardial tissue and regeneration of new myocardial tissue. 
 
     
     
         14 . The composition of  claim 13 , wherein said composition further comprises an exogenously added cytokine.

Join the waitlist — get patent alerts

Track US2015157765A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.